{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971458",
  "id": "02971458",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250722",
  "time": "1136",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0t8rbljskh5.pdf",
  "summary": "### **InhaleRx Limited (ASX: IRX) \u2013 Quarterly Report (June 2025) Summary**  \n\n#### **Key Operational & Financial Highlights:**  \n- **Clinical Progress:**  \n  - **IRX-211 (Cancer Pain):**  \n    - Phase 2 trial HREC approval secured; first patient dosing (FPI) targeted for Q3 2025.  \n    - Trial drug manufacturing commenced; active batch production upcoming.  \n  - **IRX-616a (Panic Disorder):**  \n    - Phase 1 trial preparations underway with CMAX Adelaide; HREC submission imminent.  \n    - GMP manufacturing procedures finalized.  \n\n- **Funding & Capital:**  \n  - **Clendon Facility:** First drawdown of **$248k** (total facility: **$38.5M**) for IRX-211 trial drug manufacturing.  \n  - **R&D Incentives:** Received **$402k** (2024 RDTI) + **$93k** (2023 amendment + interest).  \n\n- **Cash Flow:**  \n  - **Net operating inflow:** **$170k** (boosted by RDTI receipts).  \n  - **Closing Cash (not explicitly stated):** Infer significant liquidity from Clendon facility (covers 90% of 2\u20133-year clinical costs).  \n\n#### **Next Catalysts:**  \n- IRX-211 Phase 2: Site activation, drug delivery, patient recruitment (Q3 2025).  \n- IRX-616a Phase 1: HREC approval, manufacturing start (targeting Q4 2025 FPI).  \n\n**No material changes to capital structure or unexpected liabilities noted.**",
  "usage": {
    "prompt_tokens": 2397,
    "completion_tokens": 353,
    "total_tokens": 2750,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T03:23:44.935665"
}